A: On the package of the capsule you will find a bar code, which can be verified through following methods:

1. Scan the code: use these apps - Mashangjicha, AliHealth, Taobao, Tmall on your cell phone.

2. SMS query: send the tracking numbers to 106695001111via SMS on your cell phone.

3. Phone query: dial010-95001111and enter the tracking numbers according to the voice instructions.

4. Website query: Visithttp://www.mashangfangxin.com/and enter the tracking numbers.

Should there be any product quality issues, please call Green Valley Pharmaceuticals Manufactory at021-69219666ext. QA Department.

A: The mechanism of action of Sodium Oligomannate capsules for Alzheimer's disease is not yet clear. Published studies have shown that Sodium Oligomannate capsules act mainly by regulating gut microbiota, reducing neuroinflammation, and inhibiting amyloid beta (Aβ) deposition in the brain.

In addition, the results of animal tests have shown that Sodium Oligomannate has improved learning memory in the model mice with memory impairment induced by amyloid beta (Aβ), D-galactose, and that in the scopolamine-induced model rats.

A: Take 3 capsules (450 mg) orally, twice a day. Take on an empty stomach or with food.

A: In the Phase III clinical study of Sodium Oligomannate capsules over a total of 36 weeks (approximately 9 months), the improvement in cognitive function was consistently better in the Sodium Oligomannate group than that in the placebo group, with a statistically significant difference observed from 4 weeks after administration; the improvement effect was particularly significant from weeks 24 to 36.

Evidence of clinical safety and efficacy of Sodium Oligomannate Capsules comes from randomized controlled clinical trials lasting up to 36 weeks. If patients require longer treatment, physicians should re-evaluate the benefits and risks of continuing to take the product as recommended by clinical guidelines. If the benefit is significant and the drug can be tolerated by the patients, maintenance therapy may be considered; otherwise, discontinuation of therapy should be considered.

A: According to the product insert, the common adverse reactions of Sodium Oligomannate Capsules are: arrhythmia (1.4%, vs. 2.4% in the placebo group), dry mouth (1%, vs. 0.4% in the placebo group), hematuria (1%, vs. 0.2% in the placebo group), elevated liver enzymes (1.2-1.9%, vs. 0.2-0.8% in the placebo group), and elevated lipids (1.2%, vs. 1% in the placebo group). The degree of these adverse reactions were mild or moderate. Please contact the Pharmacovigilance (PV) Department immediately if you experience any discomfort during the treatment.

A: In patients with mild hepatic insufficiency, no dose adjustment based on liver function is required. No study data are available for patients with moderate or severe hepatic insufficiency. For patients with hepatic insufficiency, periodic testing of liver function is required during the course of this product and prompt medical attention is required for any abnormalities.

A: In patients with mild renal insufficiency, no dose adjustment based on renal function is required. No study data are available for patients with moderate or severe renal insufficiency. For patients with renal insufficiency, periodic testing of renal function is required during the course of this product and prompt medical attention is required for any abnormalities.